Medical News

RSS

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.

20 Jul 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

Affymax completes sale of all auction rate securities held by UBS

Affymax, Inc. today announced the completion of the sale at par value of all auction rate securities held by UBS AG and its affiliates in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the proceeds to retire a loan due to UBS. From April 1, 2010 through June 30, 2010, $3.7 million of the UBS ARS were settled at par value resulting in a corresponding reduction in the balance of UBS ARS and related loan since the first quarter 2010. The company now has no debt liability on its balance sheet.

20 Jul 2010

Access selects BioScrip as exclusive distribution and service partner for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

20 Jul 2010

SDIX announces multi-year collaboration with Banyan Biomarkers

SDIX, today announced a multi-year collaboration with Banyan Biomarkers, Inc. to provide products and services for Banyan's biomarker discovery work in the detection of traumatic brain injury.

20 Jul 2010

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor.

20 Jul 2010

TCG releases Will-Call Rx system for accurate prescription pick up, inventory management

TCGRx announces the release of Will-Call Rx, a computerized system for hanging and retrieving will call prescriptions. Will-Call Rx uses energy efficient LED lights to identify prescription locations and barcode scanning ensures prescription verification, accurate prescription pick up and inventory management.

20 Jul 2010

Neogen fiscal 2010 net income increases 26% to $17.5M

Neogen Corporation announced today that its net income for its 2010 fiscal year, which ended May 31, increased 26% from the previous year to $17,521,000. Net income in the fiscal year increased to $0.76 per share, compared to the prior year's $0.61, adjusted for a 3-for-2 stock split that was effective Dec. 15, 2009.

20 Jul 2010

Winston Laboratories receives NOC for CIVANEX

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Jul 2010

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.

20 Jul 2010

Advaxis signs definitive purchase agreement with Optimus

Advaxis, Inc., the live, attenuated Listeria monocytogenes immunotherapy company, announced today that it has entered into a definitive purchase agreement with Optimus Capital Partners, LLC d/b/a Optimus Life Sciences Capital Partners, LLC.

20 Jul 2010

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

Net sales for the third quarter of fiscal 2010 were $33,857,000 as compared to $38,240,000 for the same period of the prior fiscal year, a decrease of 11%. Net earnings for the third quarter of fiscal 2010 were $6,424,000 or $0.16 per diluted share, both decreases of 24%, compared to the third quarter of fiscal 2009. (Net earnings include $673,000 in Bioline acquisition costs or $0.01 per diluted share.) Diluted common shares outstanding for fiscal 2010 and 2009 were 41,151,000 and 41,191,000, respectively.

20 Jul 2010

TeleHealth Services announces dates, keynote speakers for TIGRCon10

TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.

20 Jul 2010

Spectranetics announces product reimbursement approval for SLS II

Spectranetics Corporation today announced that the Ministry of Health, Labor and Welfare in Japan has approved product reimbursement to hospitals for the Spectranetics Laser Sheath, which is used for the removal of problematic pacemaker and defibrillator cardiac leads.

20 Jul 2010

Eurotech enters multiple contracts with DynaVox for Catalyst embedded computers

Eurotech, a leading supplier of embedded technologies, products, and systems, today announces multiple contracts with DynaVox to deliver the Catalyst LP and Catalyst Module embedded computers for the DynaVox V, Vmax and Xpress™ alternative augmentative communication (AAC) devices. The combined value of these contracts is nearly 4.2M USD, with deliveries to be made in 2010 and 2011.

20 Jul 2010

MedeAnalytics 10 software platform released

MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its summer 2010 software platform release, MedeAnalytics 10, which offers performance-packed features for proactive alerting and outlier analysis. The release incorporates client input and reflects the company's ongoing investment in its analytic platform. New releases are provided to clients on a semi-annual basis and typically require no upgrades or installations.

20 Jul 2010

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.

20 Jul 2010

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a Certificate of Product Registration from the FDA Philippines, certifying that its Resurgex Select product can now be marketed as a nutritional supplement for cancer patients and other immune-compromised individuals throughout the country.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

Medical News

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

Affymax completes sale of all auction rate securities held by UBS

Access selects BioScrip as exclusive distribution and service partner for MuGard

SDIX announces multi-year collaboration with Banyan Biomarkers

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

TCG releases Will-Call Rx system for accurate prescription pick up, inventory management

Neogen fiscal 2010 net income increases 26% to $17.5M

Winston Laboratories receives NOC for CIVANEX

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Advaxis signs definitive purchase agreement with Optimus

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

TeleHealth Services announces dates, keynote speakers for TIGRCon10

Spectranetics announces product reimbursement approval for SLS II

Eurotech enters multiple contracts with DynaVox for Catalyst embedded computers

MedeAnalytics 10 software platform released

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News